Company profile
WPD Pharmaceuticals Sp. z o.o.
WPD Pharmaceuticals S.A. is a Polish biotechnology company developing innovative targeted therapies in oncology.
- Industry
- Biotechnology Research
- Employees
- 9
- Headquarters
- Ochota, Mazowieckie
- Founded
- 2017
- LinkedIn followers
- 1,372
- Office locations
- 1
WPD Pharmaceuticals Sp. z o.o. company summary
WPD Pharmaceuticals Sp. z o.o. is a company in the Biotechnology Research industry, headquartered in Ochota, Mazowieckie, founded in 2017. On LinkedIn the company has around 9 employees and 1,372 followers.
What technology does WPD Pharmaceuticals Sp. z o.o. use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About WPD Pharmaceuticals Sp. z o.o.
WPD Pharmaceuticals is developing a targeted oncology pipeline based on proprietary ligand-directed drug delivery technologies licensed from Wake Forest University School of Medicine. WPD401 is the company’s lead preclinical/early clinical oncology candidate for glioblastoma and selected solid tumors. It is a multi-targeted ligand-drug conjugate designed to recognize tumor-associated receptors, including IL-13RA2 and Eph receptors, and deliver a potent cytotoxic payload directly to cancer cells. For glioblastoma, WPD401 is being developed for local administration using convection-enhanced delivery, with the aim of maximizing intratumoral exposure while limiting systemic toxicity. The program is supported by strong translational rationale, including data from spontaneous canine glioma models, and is being advanced toward clinical development in collaboration with leading academic and technology partners. WPD103 is a targeted radiotheranostic program focused on IL-13RA2-positive tumors. The asset combines tumor-specific targeting with DOTA-based radiolabeling for potential diagnostic imaging and radionuclide therapy applications. WPD103 is designed to support patient selection, tumor visualization, and targeted treatment in cancers where IL-13RA2 expression represents a clinically relevant biomarker, including glioblastoma and other solid tumors. The program is supported by non-dilutive grant funding and forms part of WPD’s broader strategy to build an integrated targeted oncology platform.
Where is WPD Pharmaceuticals Sp. z o.o. located?
WPD Pharmaceuticals Sp. z o.o. lists 1 location.
Compare companies similar to WPD Pharmaceuticals Sp. z o.o.
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
WPD Pharmaceuticals Sp. z o.o. wpdpharmaceuticals.pl | Biotechnology Research | 9 | 2017 | Ochota, Mazowieckie |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about WPD Pharmaceuticals Sp. z o.o.
What does WPD Pharmaceuticals Sp. z o.o. do?
WPD Pharmaceuticals is developing a targeted oncology pipeline based on proprietary ligand-directed drug delivery technologies licensed from Wake Forest University School of Medicine. WPD401 is the company’s lead preclinical/early clinical oncology candidate for glioblastoma and selected solid tumors. It is a multi-targeted ligand-drug conjugate designed to recognize tumor-associated receptors, including IL-13RA2 and Eph receptors, and deliver a potent cytotoxic payload directly to cancer cells. For glioblastoma, WPD401 is being developed for local administration using convection-enhanced delivery, with the aim of maximizing intratumoral exposure while limiting systemic toxicity. The program is supported by strong translational rationale, including data from spontaneous canine glioma models, and is being advanced toward clinical development in collaboration with leading academic and technology partners. WPD103 is a targeted radiotheranostic program focused on IL-13RA2-positive tumors. The asset combines tumor-specific targeting with DOTA-based radiolabeling for potential diagnostic imaging and radionuclide therapy applications. WPD103 is designed to support patient selection, tumor visualization, and targeted treatment in cancers where IL-13RA2 expression represents a clinically relevant biomarker, including glioblastoma and other solid tumors. The program is supported by non-dilutive grant funding and forms part of WPD’s broader strategy to build an integrated targeted oncology platform.
How many employees does WPD Pharmaceuticals Sp. z o.o. have?
WPD Pharmaceuticals Sp. z o.o. has around 9 employees on LinkedIn.
Where is WPD Pharmaceuticals Sp. z o.o. headquartered?
WPD Pharmaceuticals Sp. z o.o. is headquartered in Ochota, Mazowieckie.
When was WPD Pharmaceuticals Sp. z o.o. founded?
WPD Pharmaceuticals Sp. z o.o. was founded in 2017.
Build a lead list from companies like WPD Pharmaceuticals Sp. z o.o.
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.